- Home
- TGS vs NAMS Comparison
TGS vs NAMS Comparison
Compare TGS & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TGS | NAMS |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | Argentina | Netherlands |
| Employees | N/A | 100 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.1B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | TGS | NAMS |
|---|---|---|
| Price | $29.69 | $34.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $40.00 | ★ $46.75 |
| AVG Volume (30 Days) | 332.3K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.13 | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.74 | $20.53 |
| 52 Week High | $36.35 | $42.21 |
Technical Indicators
Market Signals| Indicator | TGS | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 58.76 |
| Support Level | $28.23 | $33.83 |
| Resistance Level | $32.05 | $37.27 |
| Average True Range (ATR) | 1.17 | 1.59 |
| MACD | -0.23 | 0.52 |
| Stochastic Oscillator | 33.18 | 73.64 |
Price Performance
Historical ComparisonAbout TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a natural gas transporter in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Liquids Production and Commercialization. It generates maximum revenue from the Natural Gas Transportation segment. Geographically, it derives the majority of its revenue from Argentina.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.